Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis

Howard F. Tiano, Charles D. Loftin, Jackie Akunda, Christopher A. Lee, Judson Spalding, Alisha Sessoms, David B. Dunson, Eleanor G Rogan, Scott G. Morham, Robert C. Smart, Robert Langenbach

Research output: Contribution to journalArticle

307 Citations (Scopus)

Abstract

Nonsteroidal anti-inflammatory drugs are widely reported to inhibit carcinogenesis in humans and in rodents. These drugs are believed to act by inhibiting one or both of the known isoforms of cyclooxygenase (COX). However, COX-2, and not COX-1, is the isoform most frequently reported to have a key role in tumor development. Here we report that homozygous deficiency of either COX-1 or COX-2 reduces skin tumorigenesis by 75% in a multistage mouse skin model. Reduced tumorigenesis was observed even though the levels of stable 7,12-dimethylbenz(a)anthracene-DNA adducts were increased about 2-fold in the COX-deficient mice compared with wild-type mice. The premature onset of keratinocyte terminal differentiation appeared to be the cellular event leading to the reduced tumorigenesis because keratin 1 and keratin 10, two keratins that indicate the commitment of keratinocytes to differentiate, were expressed 8-13-fold and 10-20-fold more frequently in epidermal basal cells of the COX-1-deficient and COX-2-deficient mice, respectively, than in wild-type mice. Papillomas on the COX-deficient mice also displayed the premature onset of keratinocyte terminal differentiation. However, loricrin, a late marker of epidermal differentiation, was not significantly altered, suggesting that it was the early stages of keratinocyte differentiation that were primarily affected by COX deficiency. Because keratin 5, a keratin associated with basal cells, was detected differently in papillomas of COX-1-deficient as compared with COX-2-deficient mice, it appears that the isoforms do not have identical roles in papilloma development. Interestingly, apoptosis, a cellular process associated with nonsteroidal anti-inflammatory drug-induced inhibition of tumorigenesis, was not significantly altered in the epidermis or in papillomas of the COX-deficient mice. Thus, both COX-1 and COX-2 have roles in keratinocyte differentiation, and we propose that the absence of either isoform causes premature terminal differentiation of initiated keratinocytes and reduced tumor formation.

Original languageEnglish (US)
Pages (from-to)3395-3401
Number of pages7
JournalCancer Research
Volume62
Issue number12
StatePublished - Jun 15 2002

Fingerprint

Cyclooxygenase 1
Cyclooxygenase 2
Keratinocytes
Prostaglandin-Endoperoxide Synthases
Carcinogenesis
Papilloma
Skin
Protein Isoforms
Keratins
Anti-Inflammatory Agents
Keratin-1
Keratin-10
Keratin-5
Pharmaceutical Preparations
Differentiation Antigens
Epidermis
Rodentia
Neoplasms
Apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tiano, H. F., Loftin, C. D., Akunda, J., Lee, C. A., Spalding, J., Sessoms, A., ... Langenbach, R. (2002). Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Research, 62(12), 3395-3401.

Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. / Tiano, Howard F.; Loftin, Charles D.; Akunda, Jackie; Lee, Christopher A.; Spalding, Judson; Sessoms, Alisha; Dunson, David B.; Rogan, Eleanor G; Morham, Scott G.; Smart, Robert C.; Langenbach, Robert.

In: Cancer Research, Vol. 62, No. 12, 15.06.2002, p. 3395-3401.

Research output: Contribution to journalArticle

Tiano, HF, Loftin, CD, Akunda, J, Lee, CA, Spalding, J, Sessoms, A, Dunson, DB, Rogan, EG, Morham, SG, Smart, RC & Langenbach, R 2002, 'Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis', Cancer Research, vol. 62, no. 12, pp. 3395-3401.
Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Research. 2002 Jun 15;62(12):3395-3401.
Tiano, Howard F. ; Loftin, Charles D. ; Akunda, Jackie ; Lee, Christopher A. ; Spalding, Judson ; Sessoms, Alisha ; Dunson, David B. ; Rogan, Eleanor G ; Morham, Scott G. ; Smart, Robert C. ; Langenbach, Robert. / Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. In: Cancer Research. 2002 ; Vol. 62, No. 12. pp. 3395-3401.
@article{65f86b3ed10a4df39f03fedae006f5a0,
title = "Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis",
abstract = "Nonsteroidal anti-inflammatory drugs are widely reported to inhibit carcinogenesis in humans and in rodents. These drugs are believed to act by inhibiting one or both of the known isoforms of cyclooxygenase (COX). However, COX-2, and not COX-1, is the isoform most frequently reported to have a key role in tumor development. Here we report that homozygous deficiency of either COX-1 or COX-2 reduces skin tumorigenesis by 75{\%} in a multistage mouse skin model. Reduced tumorigenesis was observed even though the levels of stable 7,12-dimethylbenz(a)anthracene-DNA adducts were increased about 2-fold in the COX-deficient mice compared with wild-type mice. The premature onset of keratinocyte terminal differentiation appeared to be the cellular event leading to the reduced tumorigenesis because keratin 1 and keratin 10, two keratins that indicate the commitment of keratinocytes to differentiate, were expressed 8-13-fold and 10-20-fold more frequently in epidermal basal cells of the COX-1-deficient and COX-2-deficient mice, respectively, than in wild-type mice. Papillomas on the COX-deficient mice also displayed the premature onset of keratinocyte terminal differentiation. However, loricrin, a late marker of epidermal differentiation, was not significantly altered, suggesting that it was the early stages of keratinocyte differentiation that were primarily affected by COX deficiency. Because keratin 5, a keratin associated with basal cells, was detected differently in papillomas of COX-1-deficient as compared with COX-2-deficient mice, it appears that the isoforms do not have identical roles in papilloma development. Interestingly, apoptosis, a cellular process associated with nonsteroidal anti-inflammatory drug-induced inhibition of tumorigenesis, was not significantly altered in the epidermis or in papillomas of the COX-deficient mice. Thus, both COX-1 and COX-2 have roles in keratinocyte differentiation, and we propose that the absence of either isoform causes premature terminal differentiation of initiated keratinocytes and reduced tumor formation.",
author = "Tiano, {Howard F.} and Loftin, {Charles D.} and Jackie Akunda and Lee, {Christopher A.} and Judson Spalding and Alisha Sessoms and Dunson, {David B.} and Rogan, {Eleanor G} and Morham, {Scott G.} and Smart, {Robert C.} and Robert Langenbach",
year = "2002",
month = "6",
day = "15",
language = "English (US)",
volume = "62",
pages = "3395--3401",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis

AU - Tiano, Howard F.

AU - Loftin, Charles D.

AU - Akunda, Jackie

AU - Lee, Christopher A.

AU - Spalding, Judson

AU - Sessoms, Alisha

AU - Dunson, David B.

AU - Rogan, Eleanor G

AU - Morham, Scott G.

AU - Smart, Robert C.

AU - Langenbach, Robert

PY - 2002/6/15

Y1 - 2002/6/15

N2 - Nonsteroidal anti-inflammatory drugs are widely reported to inhibit carcinogenesis in humans and in rodents. These drugs are believed to act by inhibiting one or both of the known isoforms of cyclooxygenase (COX). However, COX-2, and not COX-1, is the isoform most frequently reported to have a key role in tumor development. Here we report that homozygous deficiency of either COX-1 or COX-2 reduces skin tumorigenesis by 75% in a multistage mouse skin model. Reduced tumorigenesis was observed even though the levels of stable 7,12-dimethylbenz(a)anthracene-DNA adducts were increased about 2-fold in the COX-deficient mice compared with wild-type mice. The premature onset of keratinocyte terminal differentiation appeared to be the cellular event leading to the reduced tumorigenesis because keratin 1 and keratin 10, two keratins that indicate the commitment of keratinocytes to differentiate, were expressed 8-13-fold and 10-20-fold more frequently in epidermal basal cells of the COX-1-deficient and COX-2-deficient mice, respectively, than in wild-type mice. Papillomas on the COX-deficient mice also displayed the premature onset of keratinocyte terminal differentiation. However, loricrin, a late marker of epidermal differentiation, was not significantly altered, suggesting that it was the early stages of keratinocyte differentiation that were primarily affected by COX deficiency. Because keratin 5, a keratin associated with basal cells, was detected differently in papillomas of COX-1-deficient as compared with COX-2-deficient mice, it appears that the isoforms do not have identical roles in papilloma development. Interestingly, apoptosis, a cellular process associated with nonsteroidal anti-inflammatory drug-induced inhibition of tumorigenesis, was not significantly altered in the epidermis or in papillomas of the COX-deficient mice. Thus, both COX-1 and COX-2 have roles in keratinocyte differentiation, and we propose that the absence of either isoform causes premature terminal differentiation of initiated keratinocytes and reduced tumor formation.

AB - Nonsteroidal anti-inflammatory drugs are widely reported to inhibit carcinogenesis in humans and in rodents. These drugs are believed to act by inhibiting one or both of the known isoforms of cyclooxygenase (COX). However, COX-2, and not COX-1, is the isoform most frequently reported to have a key role in tumor development. Here we report that homozygous deficiency of either COX-1 or COX-2 reduces skin tumorigenesis by 75% in a multistage mouse skin model. Reduced tumorigenesis was observed even though the levels of stable 7,12-dimethylbenz(a)anthracene-DNA adducts were increased about 2-fold in the COX-deficient mice compared with wild-type mice. The premature onset of keratinocyte terminal differentiation appeared to be the cellular event leading to the reduced tumorigenesis because keratin 1 and keratin 10, two keratins that indicate the commitment of keratinocytes to differentiate, were expressed 8-13-fold and 10-20-fold more frequently in epidermal basal cells of the COX-1-deficient and COX-2-deficient mice, respectively, than in wild-type mice. Papillomas on the COX-deficient mice also displayed the premature onset of keratinocyte terminal differentiation. However, loricrin, a late marker of epidermal differentiation, was not significantly altered, suggesting that it was the early stages of keratinocyte differentiation that were primarily affected by COX deficiency. Because keratin 5, a keratin associated with basal cells, was detected differently in papillomas of COX-1-deficient as compared with COX-2-deficient mice, it appears that the isoforms do not have identical roles in papilloma development. Interestingly, apoptosis, a cellular process associated with nonsteroidal anti-inflammatory drug-induced inhibition of tumorigenesis, was not significantly altered in the epidermis or in papillomas of the COX-deficient mice. Thus, both COX-1 and COX-2 have roles in keratinocyte differentiation, and we propose that the absence of either isoform causes premature terminal differentiation of initiated keratinocytes and reduced tumor formation.

UR - http://www.scopus.com/inward/record.url?scp=0037096879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037096879&partnerID=8YFLogxK

M3 - Article

C2 - 12067981

AN - SCOPUS:0037096879

VL - 62

SP - 3395

EP - 3401

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 12

ER -